Inhibitor Therapeutics (INTI) S-1/A 22 Jul 15 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2015
Document And Entity Information [Abstract]
Document Type	S-1/A
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Trading Symbol	HPPI
Entity Registrant Name	HedgePath Pharmaceuticals, Inc.
Entity Central Index Key	1,042,418
Entity Filer Category	Smaller Reporting Company

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 83,951	$ 365,161	$ 217
Other current assets	43,723	97,817	10,000
Total current assets	127,674	462,978	10,217
Total assets	127,674	462,978	10,217
Current liabilities:
Accounts payable	493,877	324,966	287,072
Notes payable, related party			68,428
Other liabilities	74,689	75,933	52,500
Accrued interest			1,923
Due to related party			366,130
Total current liabilities	568,566	400,899	776,053
Total liabilities	568,566	$ 400,899	$ 776,053
Commitments and contingencies
Stockholders' (deficit) equity:
Common stock	21,142	$ 21,142	$ 1,889
Additional paid-in capital	32,683,593	32,263,890	27,479,913
Accumulated deficit	(33,145,627)	(32,222,953)	(28,247,655)
Total stockholders' (deficit) equity	(440,892)	62,079	(765,836)
Preferred stock value		0
Total liabilities and stockholders' (deficit) equity	$ 127,674	462,978	10,217
Series A Preferred Stock [Member]
Stockholders' (deficit) equity:
Total stockholders' (deficit) equity		0	17
Preferred stock value		$ 0	$ 17

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares authorized		9,500,000	9,500,000
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Common stock, par value	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	340,000,000	340,000,000	340,000,000
Common stock, shares issued	211,419,937	211,419,937	18,888,971
Common stock, shares outstanding	211,419,937	211,419,937	18,888,971
Series A Preferred Stock [Member]
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares authorized		500,000	500,000
Preferred stock, shares issued		0	170,001
Preferred stock, shares outstanding		0	170,001

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Total revenues	$ 0	$ 0	$ 0	$ 0
Expenses:
Chapter 11 expenses				117,324
Research and development	313,017	25,325	2,430,735	1,065,169
General and administrative	609,657	161,605	1,507,082	817,316
Total expenses	922,674	186,930	3,937,817	1,999,809
Loss from operations	(922,674)	(186,930)	(3,937,817)	(1,999,809)
Interest expense		(9,558)	(37,481)	(1,923)
Gain on reorganization:
Gain on settlement of pre-petition claims			0	166,676
Net loss	$ (922,674)	$ (196,488)	$ (3,975,298)	$ (1,835,056)
Basic and diluted loss per share		$ (0.01)	$ (0.04)	$ (0.10)
Weighted average common shares outstanding	211,419,937	18,888,971	95,884,524	17,940,586

Condensed Statement of Stockhol

Condensed Statement of Stockholders' (Deficit) Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Common Stock Subscription Receivable - Related Party [Member]	Accumulated Deficit [Member]	Series A Preferred Stock [Member]
Beginning balance at Dec. 31, 2012	$ (132,784)	$ 0	$ 26,279,815		$ (26,412,599)	$ 0
Beginning balance, shares at Dec. 31, 2012		15,560,504				0
Issuance of stock	1,050,004		1,049,987			$ 17
Issuance of stock, shares						170,001
Issuance of restricted stock in lieu of cash payment under the Bankruptcy Plan	152,000	$ 0	152,000			$ 0
Issuance of restricted stock in lieu of cash payment under the Bankruptcy Plan, shares		3,328,467
Initiation of par value pursuant to agreement and plan of merger and reorganization		$ 1,889	(1,889)
Net loss	(1,835,056)				(1,835,056)
Ending balance at Dec. 31, 2013	(765,836)	$ 1,889	27,479,913		(28,247,655)	$ 17
Ending balance, shares at Dec. 31, 2013		18,888,971				170,001
Issuance of preferred and common stock in debt forgiveness transaction	189,768	$ 253	189,508			$ 7
Issuance of preferred and common stock in debt forgiveness transaction, shares		2,530,227				71,636
Issuance of stock	250,000	$ 2,000	1,498,000	$ (1,250,000)
Issuance of stock, shares		20,000,000
Issuance of warrants for debt forgiveness	450,000		450,000
Issuance of common stock warrants in acquisition of research and development and development license agreement	619,134		619,134
Issuance of preferred stock in acquisition of research and development license agreement	1,290,726		1,290,700			$ 26
Issuance of preferred stock in acquisition of research and development license agreement, shares						258,363
Collection of stock subscription receivable	1,250,000			$ 1,250,000
Conversion of preferred stock to common stock		$ 17,000	(16,950)			$ (50)
Conversion of preferred stock to common stock, shares		170,000,739				(500,000)
Stock based compensation	753,585		753,585
Net loss	(3,975,298)				(3,975,298)
Ending balance at Dec. 31, 2014	62,079	$ 21,142	32,263,890		(32,222,953)	$ 0
Ending balance, shares at Dec. 31, 2014		211,419,937
Stock based compensation	419,703		419,703
Net loss	(922,674)				(922,674)
Ending balance at Mar. 31, 2015	$ (440,892)	$ 21,142	$ 32,683,593		$ (33,145,627)
Ending balance, shares at Mar. 31, 2015		211,419,937

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Operating activities:
Net loss	$ (922,674)	$ (196,488)	$ (3,975,298)	$ (1,835,056)
Adjustments to reconcile net loss to net cash flows from operating activities:
In-process research and development purchased with the issuance of preferred stock and common stock warrants			1,909,860	1,020,004
Non-cash interest expense		6,666	34,819
Share-based compensation	419,703		753,585
Changes in assets and liabilities:
Other current assets			(87,817)	68,733
Prepaid expense and other current assets	54,094
Accounts payable and other current liabilities	167,667	81,317	61,327	46,645
Net cash flows provided by (used in) operating activities before reorganization items			(1,303,524)	(699,674)
Reorganization items:
Gain on reorganization			0	(166,676)
Decrease in liabilities subject to compromise				(357,265)
Net cash flows provided by (used in) operating activities	(281,210)	(108,505)	(1,303,524)	(1,223,615)
Financing activities:
Proceeds from related party advances		108,744	273,638	366,130
Payments on notes payable			(105,170)
Proceeds from sale of common stock and collection of stock subscription receivable, related party			1,500,000
Net cash flows from financing activities		108,744	1,668,468	366,130
Net change in cash and cash equivalents	(281,210)	239	364,944	(857,485)
Cash and cash equivalents at beginning of period	365,161	217	217	857,702
Cash and cash equivalents at end of period	$ 83,951	$ 456	365,161	217
Cash paid for interest			2,005
Supplemental disclosure of non-cash financing activities:
Reclassification of deposit to additional paid-in capital				30,000
Promissory notes issued in payment of related party obligations				68,428
Board Members and Officers [Member]
Supplemental disclosure of non-cash financing activities:
Stock payments to officers and directors (liabilities subject to compromise) in lieu of cash payments under the Bankruptcy Plan				$ 152,000
Preferred Stock And Common Stock [Member]
Supplemental disclosure of non-cash financing activities:
Issuance of preferred and common stock in debt forgiveness transaction			189,768
Warrants [Member]
Supplemental disclosure of non-cash financing activities:
Issuance of preferred and common stock in debt forgiveness transaction			$ 450,000

Corporate Overview

Corporate Overview	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Corporate Overview	1. Corporate overview: Overview The accompanying unaudited condensed financial statements of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”, “HPPI”, “we”, “us” or similar terminology), have been prepared by the Company without audit. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows as of March 31, 2015, and for all periods presented, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted pursuant to the Securities and Exchange Commission (“SEC”) rules and regulations. These unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014, which are included in the Company’s 2014 Annual Report on Form 10-K, filed with the SEC on February 13, 2015 (the “2014 Annual Report”). The accompanying condensed balance sheet at December 31, 2014 has been derived from the audited financial statements at that date, but does not include all information and footnotes required by GAAP for complete financial statements. As used herein, the term “Common Stock” means the Company’s common stock, $0.0001 par value per share. The results of operations for the three month period ended March 31, 2015 are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year. Readers of this Quarterly Report are strongly encouraged to review the risk factors relating to the Company which are set forth in the 2014 Annual Report and our other filings with the SEC. The accompanying financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities of the Company in the normal course of business. If the Company is unable to raise required funding to continue to pursue its business plan, it may have to cease operations. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Nature of the Business and Background The Company is a biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers. The Company’s preliminary focus is on the development of therapies for skin, lung and prostate cancers in the United States of America (“U.S.”) market, with the first indication targeting basal cell carcinoma in patients with Basal Cell Carcinoma Nevus Syndrome (also known as Gorlin Syndrome). The Company’s proposed therapy is based upon the use of SUBA-Itraconazole, a patented, oral formulation of the currently marketed anti-fungal drug itraconazole. The Company believes that the dosing of oral capsules of this formulation can affect the Hedgehog signaling pathway, a major regulator of many fundamental cellular processes, which, in turn, can impact the development and growth of cancers such as basal cell carcinoma. Itraconazole has been approved by the U.S. Food and Drug Administration (“FDA”) for, and has been extensively used to treat, fungal infections and has an extensive history of safe and effective use in humans. The Company has developed, optioned and licensed intellectual property and know-how related to the treatment of cancer patients using itraconazole and has applied for patents to cover the Company’s inventions. Mayne Pharma Supply and License Agreement On September 3, 2013, the Company entered into an exclusive Supply and License Agreement (the “Supply and License Agreement”) with Mayne Pharma International Pty Ltd., a company incorporated in Australia (“MPI”), pursuant to which MPI agreed to: (i) supply the Company with its patented formulation of the drug itraconazole in a particular dose formulation (the “Product”) for the treatment of human patients with cancer via oral administration (the “Field”) (with the initial areas of investigation being skin, lung and prostate cancer) in the United States (the “Territory”), (ii) provide the Company with an exclusive license to use and develop the intellectual property related to the Product in the Field and in the Territory and (iii) participate in a joint development committee with the Company to clinically develop the Product in the Field and in the Territory. The Company expects to pursue the development of the Product for treatment of a variety of cancers (initially basal cell carcinoma in patients with Gorlin Syndrome) with a focus on clinical development, seeking regulatory approvals and, if regulatory approval is obtained, marketing in the U.S. Subject to earlier termination if certain conditions (“Conditions”) were not met (which Conditions were subsequently eliminated as described further below), the term of the Supply and License Agreement was until the later of: (i) 10 years from the target launch date of the Product for the treatment of human patients with cancer via oral administration or (ii) the date on which all issued patents of MPI or any of its affiliates referred to in the Supply and License Agreement had lapsed or expired. The Company entered into Amendment No. 1 and Amendment No. 2 to the Supply and License Agreement (the “Amended Supply and License Agreement”) with MPI to extend the date by which the Conditions were to be met to May 30, 2014. On June 24, 2014, the Company and Mayne Pharma Ventures Pty Ltd (“Mayne Pharma”), an Australian company and assignee of MPI’s rights, along with Nicholas J. Virca, the Company’s President and Chief Executive Officer (“Virca”), Frank O’Donnell, Jr., M.D., the Company’s Executive Chairman (“O’Donnell”) and HPLLC, consummated a series of related transactions to fulfill the Conditions in a manner mutually acceptable to the Company and Mayne Pharma. In connection therewith, the Company and Mayne Pharma entered into, among other agreements, an Amended and Restated Supply and License Agreement as of June 24, 2014 (the “Amended and Restated Supply and License Agreement”) principally to eliminate the Conditions and related early termination rights of Mayne Pharma.	1. Corporate overview: Overview The accompanying audited financial statements of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”, “HPPI”, “we”, “us” or similar terminology) as successor to Commonwealth Biotechnologies, Inc., a Virginia corporation (“CBI”), have been prepared by the Company as a going concern. As used herein, the term “Common Stock” means the Company’s common stock, $0.0001 par value per share. Nature of the Business The Company is a biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers. The Company’s preliminary focus is on the development of therapies for skin, lung and prostate cancers in the U.S. market, with the first indication targeting basal cell carcinoma in patients with Basal Cell Carcinoma Nevus Syndrome (also known as Gorlin Syndrome). The Company’s proposed therapy is based upon the use of SUBA-Itraconazole, which is a patented, oral formulation of the currently marketed anti-fungal drug itraconazole. The Company believes that the dosing of oral capsules of this formulation can affect the Hedgehog signaling pathway, a major regulator of many fundamental cellular processes, which, in turn, can impact the development and growth of cancers such as basal cell carcinoma. Itraconazole is FDA approved for, and extensively used to, treat fungal infections and has an extensive history of safe and effective use in humans. The Company has developed, optioned and licensed intellectual property and know-how related to the treatment of cancer patients using itraconazole and has applied for patents to cover the Company’s inventions. Pre-Bankruptcy and Emergence from Bankruptcy CBI was a specialized life sciences outsourcing business that offered certain peptide-based discovery chemistry and biology products and services. On January 20, 2011, CBI filed a voluntary petition captioned In re Commonwealth Biotechnologies, Inc., Case No. 11-30381-KRH On August 12, 2013, in furtherance of CBI’s emergence from bankruptcy as described further below, CBI effected a “short-form” reincorporation merger with HPPI, a newly created and wholly owned Delaware subsidiary of CBI, pursuant to which CBI merged with and into HPPI, with HPPI surviving the merger and with the effect of CBI becoming reincorporated as a Delaware corporation and changing its corporate name. Each outstanding share of CBI was converted into one share of HPPI. HPPI’s Certificate of Incorporation (and thus the Certificate of Incorporation of the surviving company) authorizes the issuance of up to 340,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share. The par value of the common stock was changed from no par value to $0.0001, which par value is customary for newly formed Delaware corporations. As described further below, the Company’s present business is the development of the currently-marketed drug itraconazole (currently approved by the U.S. Food and Drug Administration (the “FDA”) as an anti-fungal agent) for the treatment of certain cancers. On January 4, 2013, CBI filed an Amended Plan of Reorganization (the “Plan”) with the Bankruptcy Court. The Plan was approved by a vote of creditors and CBI stockholders on March 21, 2013. CBI received an auction fee of $30,000 from Hedgepath, LLC, a Florida limited liability company, (which fee was a binding, irrevocable offer for the purchase of a portion of CBI’s equity interests) in addition to the contribution of Assets as described below. Hedgepath, LLC was the winning bidder for CBI, which is more fully described below in Post-Bankruptcy Business of HPPI-General. On March 29, 2013, the Bankruptcy Court entered an order (the “Confirmation Order”) confirming the Plan pursuant to Chapter 11 of the Bankruptcy Code. Under the terms of the Plan, and pursuant to the Contribution Agreement (as described further below), Hedgepath, LLC contributed and assigned the Assets (as such term is defined below) to HPPI, as the reorganized debtor, in exchange for the right to receive 90% of the then fully diluted voting equity in HPPI (in the form of the Series A Preferred Stock) on the date of issuance, with the prior stockholders of CBI retaining approximately 10% voting equity in HPPI, represented by 100% of the issued and outstanding shares of Common Stock. Contribution Agreement On August 13, 2013, the Company entered into a Contribution Agreement, dated as of August 13, 2013 (the “Contribution Agreement”), by and between the Company and Hedgepath, LLC (“HPLLC”) pursuant to which, and subject to the terms and conditions contained therein, in exchange for the right to receive 170,001 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Series A Preferred Stock”), representing 90% of the fully diluted voting securities of the Company as of the date of issuance (or 170,000,739 shares of Common Stock on an as converted basis), Hedgepath, LLC contributed and/or assigned various assets and contract rights to the Company associated with the going forward business of the Company (collectively, the “Assets”) to the Company as described below. (i) U.S. Provisional Patent Application 61-813,122, “Prostate-Specific Antigen as Biomarker for Hedgehog Pathway Inhibitor Treatment and Prognostic Monitoring of Prostate Cancer” (previously assigned to Hedgepath, LLC by Dr. Frank E. O’Donnell, Jr. and Nicholas J. Virca, as inventors); (ii) U.S. Provisional Patent Application 61-813,823, “Treatment and Prognostic Monitoring of Cancer Using Hedgehog Pathway Inhibitors” (previously assigned to Hedgepath, LLC by Dr. Frank E. O’Donnell, Jr. and Nicholas J. Virca, as inventors); (iii) Assignment of Patents, dated November 1, 2012, by Dr. Frank E. O’Donnell, Jr. in favor of Hedgepath, LLC; (iv) Assignment of Patents, dated November 1, 2012, by Nicholas J. Virca in favor of Hedgepath, LLC; (v) Consulting Agreement, dated and effective as of September 1, 2012, by and between HPPI (as successor to Hedgepath, LLC) and Emmanuel Antonarakis, MD (“Antonarakis”). (vi) Confidentiality and Intellectual Property Assignment Agreement, dated and effective September 1, 2012, between Antonarakis and HPPI (as successor to Hedgepath, LLC), which includes all intellectual property, know-how and other assets assigned to Hedgepath, LLC by Antonarakis under such agreement. (vii) Consulting Agreement, effective as of April 11, 2013, by and between Hedgepath, LLC and Arianne Consulting, Inc. (“Arianne”); and (viii) Confidentiality and Intellectual Property Assignment Agreement, dated and effective April 11, 2013, between Arianne and Hedgepath, LLC, which includes all intellectual property, know-how and other assets assigned to Hedgepath, LLC by Arianne under such agreement. The Contribution Agreement was entered into to carry out the purposes and intent of the Plan filed by CBI and confirmed by the Bankruptcy Court in connection with the Chapter 11 case. Hedgepath, LLC is a development stage pharmaceutical company. Since its formation in late 2011, Hedgepath, LLC has sought, among other pharmaceutical business opportunities, to acquire technology rights and to conduct activities related to the development of the currently-marketed drug itraconazole (currently FDA approved as an anti-fungal agent) for the treatment of certain cancers (the “Itra Business Opportunity”). Hedgepath, LLC had expended approximately $0.1 million acquiring assets and developing the ITRA Business Opportunity including approximately $82,500 on technical and medical consulting and $15,000 on option fees related to intellectual property agreement that has since expired. In accordance with the Plan, and as a result of the transactions contemplated by the Contribution Agreement, from and after August 13, 2013, HPPI has been engaged in the Itra Business Opportunity. The Assets contributed to the Company by Hedgepath, LLC represent the assets and rights heretofore developed or acquired by Hedgepath, LLC related to the Itra Business Opportunity, and by virtue of the Contribution Agreement, the Company acquired all of Hedgepath, LLC’s right, title and interest in and to the Assets. As part of the Contribution Agreement, Hedgepath, LLC, which owned a certain claim against CBI in the amount of $52,500, payable to a third party service provider, contributed such claim to the Company. HPPI has agreed to issue to such service provider a number of restricted shares of its Common Stock to be determined based on the valuation of the shares to be issued to purchasers in connection with HPPI’s planned $5 million offering of securities as described in the Plan. Such shares of Common Stock are to be issued to such service provider within five (5) business days of the final determination of such valuation (as memorialized in the final transaction documentation for such offering). Hedgepath, LLC did not contribute any of its liabilities to the Company in connection with the Contribution Agreement, and retained all of its assets other than those related to the Itra Business Opportunity. In conjunction with the execution of the Contribution Agreement, the Company has expensed, as in-process research and development cost, approximately $1.0 million. The value was calculated by taking 90% of the market capitalization on the date the assets were contributed to reflect the 90% ownership exchanged for the assets contributed by Hedgepath, LLC. Mayne Pharma Supply and License Agreement On September 3, 2013, the Company entered into an exclusive Supply and License Agreement (the “Supply and License Agreement”) with Mayne Pharma International Pty Ltd., a company incorporated in Australia (“MPI”), pursuant to which MPI agreed to: (i) supply the Company with its patented formulation of the drug itraconazole, in a particular dose formulation (the “Product”) for the treatment of human patients with cancer via oral administration (the “Field”) (with the initial areas of investigation being skin, lung and prostate cancer) in the United States (the “Territory”), (ii) provide the Company with an exclusive license to use and develop the intellectual property related to the Product in the Field and in the Territory and (iii) participate in a joint development committee with the Company to clinically develop the Product in the Field and in the Territory. The Company expects to pursue the development of the Product for treatment of a variety of cancers (initially basal cell carcinoma in patients with Gorlin Syndrome) with a focus on clinical development, seeking regulatory approvals and, if regulatory approval is obtained, marketing in the United States. Subject to earlier termination if certain conditions (“Conditions”) were not met (which Conditions were subsequently eliminated as described further below), the term of the Supply and License Agreement shall last until the later of: (i) 10 years from the target launch date of the Product for the treatment of human patients with cancer via oral administration or (ii) the date on which all issued patents of MPI or any of its affiliates referred to in the Supply and License Agreement have lapsed or expired. The Company entered into Amendment No. 1 and Amendment No. 2 to the Supply and License Agreement (the “Amended Supply and License Agreement”) with MPI to extend the date by which the Conditions were to be met from December 16, 2013 to June 30, 2014. On June 24, 2014, the Company and Mayne Pharma Ventures Pty Ltd (“Mayne Pharma”), an Australian company and assignee of MPI’s rights, along with Nicholas J. Virca, the Company’s President and Chief Executive Officer (“Virca”), Frank O’Donnell, Jr., M.D., the Company’s Executive Chairman (“O’Donnell”) and HPLLC, consummated a series of related transactions to fulfill the Conditions in a manner mutually acceptable to the Company and Mayne Pharma. In connection therewith, the Company and Mayne Pharma entered into an Amended and Restated Supply and License Agreement as of June 24, 2014 (the “Amended and Restated Supply and License Agreement”) principally to eliminate the Conditions and related early termination rights of Mayne Pharma. Mayne Pharma Securities Purchase Agreement On June 24, 2014, the Company and Mayne Pharma entered into a Securities Purchase Agreement (the “Mayne Purchase Agreement”). Pursuant to the Mayne Purchase Agreement, the Company (i) issued 258,363 shares of Series A Preferred Stock (the “Mayne Series A Shares”) and (ii) issued, upon closing of a separate Securities Purchase Agreement, dated June 24, 2014 (as described further below, the “HPLLC Purchase Agreement”) by and between the Company and HPLLC, a warrant to purchase 10,250,569 shares of Common Stock (the “Mayne Make-Up Warrant”). The Mayne Series A Shares converted into 87,843,897 shares of Common Stock on August 14, 2014 pursuant to the terms of the Equity Holders Agreement (discussed below) and in accordance with the terms of the Series A Preferred Stock. The Mayne Make-Up Warrant has an exercise price of $0.0878 per share and may be exercised at any time, from time to time, by Mayne Pharma prior to the expiration on June 24, 2019. In conjunction with the execution of the Mayne Purchase Agreement, the Company has expensed, as in-process research and development costs, approximately $1.9 million for the fair value of the preferred stock and warrant issued. The value of the issued stock was calculated by taking approximately 42% of the market capitalization on the date the agreement was entered into to reflect the 42% ownership exchanged for entering into the agreement. The value of the warrant was calculated by using the Black-Scholes valuation model that uses assumptions for expected volatility (104.9%), expected dividends (none), expected term (5 years), and risk-free interest rate (1.7%). Expected volatilities are based on historical volatilities of peer companies. The risk-free rate is based upon the U.S. Treasury yield curve in effect at the time of the grant for the period of the expected term. HPLLC Purchase Agreement On June 24, 2014, the Company and HPLLC entered into the HPLLC Purchase Agreement, pursuant to which the Company sold HPLLC 20,000,000 shares of Common Stock at a purchase price of $0.075 per share for an aggregate purchase price of $1,500,000, which monies were funded in monthly installments through December 2014 pursuant to the promissory note (the “HPLLC Note”) issued by HPLLC to the Company on June 24, 2014. Funds received under this transaction are being used by the Company for research and development as well as for general and administrative expenses. Equity Holders Agreement On June 24, 2014, in fulfillment of one of the Conditions of the Supply and License Agreement, and as a condition of the Mayne Purchase Agreement and in consideration for Mayne Pharma not exercising its right to terminate the Supply and License Agreement, the Company, Mayne Pharma, HPLLC, O’Donnell and Virca (together, the “Equity Holder Parties”) entered into an Equity Holders Agreement (the “Equity Holders Agreement”). The Equity Holders Agreement governs the rights and obligations of each of the parties as they pertain to the Company’s securities and to the present and future governance of the Company. Pursuant to the Equity Holders Agreement: • Mayne Pharma and HPLLC each agreed not to offer, pledge, sell, contract to sell, swap or enter into any other transfer arrangement any of their Company securities until June 24, 2015 (the “Lock-Up Period”) without prior written consent of the other Equity Holder Parties, except for in limited circumstances as described in the Equity Holders Agreement; • Mayne Pharma and HPLLC each agreed that on August 14, 2014 (or within 2 business days thereafter) each would convert all of its Series A Preferred Stock into shares of Common Stock at a rate of 1 for 340 shares of Common Stock, notwithstanding any prior contractual conversion arrangements. Subsequently, on August 14, 2014, all 500,000 shares of Series A Preferred Stock converted into 170,000,739 shares of Common Stock of the Company; • Mayne Pharma, HPLLC, Virca and O’Donnell each agreed that during the Lock-Up Period none of them will own greater than 49.5% of the Common Stock of the Company on a fully-diluted basis (such ownership to include individual and affiliate ownership) and that after the Lock-Up Period and until June 24, 2019, each of the Equity Holder Parties will provide written notice to each of the other Equity Holder Parties if their ownership (together with affiliates) exceeds, or is going to exceed, 49.5%; • Mayne Pharma and its affiliates (the “Mayne Pharma Group”) have been granted a right of first refusal to purchase a pro rata share of any new securities issued by the Company, such pro rata share to be determined based upon the number of shares of Common Stock held by Mayne Pharma Group on a fully diluted basis as compared to the number of shares of Common Stock outstanding immediately prior to the offering of the new securities on a fully diluted basis; • Mayne Pharma has been granted the right until June 24, 2016 to introduce accredited investors to the Company to participate in a private offering of the Company’s securities (with some exceptions as described in the Equity Holders Agreement). In the event that the Company contemplates a private offering of its securities, such accredited investors introduced by Mayne Pharma to have the right to participate in up to 50% of the private offering; • Mayne Pharma has the right to immediately designate one director to the Company’s Board of Directors (the “Board”) and to designate a second director if the size of the Board is increased to seven directors until the earlier to occur of: (i) the date that the Amended and Restated Supply and License Agreement is terminated or expires, or (ii) the date on which the Mayne Pharma Group ceases to own ten percent (10%) or more of the issued and outstanding Common Stock on a fully diluted basis (the “Voting Rights Termination Date”); • The Equity Holder Parties agree that if HPLLC fails to satisfy certain performance goals, defaults under the HPLLC Note, or breaches any provisions of the HPLLC Note then the Company has the right to declare that 17,647 shares of Series A Preferred Stock (or the Common Stock equivalent upon conversion thereof) be forfeited and Mayne Pharma has the right to purchase such forfeited shares; and • The Equity Holder Parties agree that if HPLLC defaults under the HPLLC Note or breaches any provisions of the HPLLC Note, then Mayne Pharma has the right to demand the resignation of O’Donnell. As of December 31, 2014, no such default or breach occurred and the note was satisfied in full. In addition to the foregoing, the Equity Holder Parties also agreed that the Company would seek to meet certain goals for the commercialization of the Product (the “Commercialization Goals”) and certain funding goals for the Company (the “Funding Goals”). In the event that the Company fails to achieve the Commercialization Goals or the Funding Goals, Mayne Pharma has the right to demand the resignation of O’Donnell and/or Virca from their positions with the Company. In the event that O’Donnell or Virca do not submit their resignations in a timely manner, Mayne Pharma can terminate the Amended and Restated Supply and License Agreement. Additionally, if the Commercialization Goals are not achieved, the Company has the right to declare that HPLLC forfeit 17,647 shares of Series A Preferred Stock (now equal to approximately six million shares of Common Stock following the conversion of the Series A Preferred Stock in August 2014). If O’Donnell or Virca are required to resign pursuant to the Equity Holders Agreement, then, notwithstanding the Employment Agreement between the Company and Virca or the Executive Chairman Agreement between the Company and O’Donnell, no severance, compensation, consideration or other payment will be due or payable in connection therewith and O’Donnell or Virca, as the case may be, will forfeit all then unvested options, warrants, restricted stock units, or other right to acquire Common Stock (or securities convertible into Common Stock) and will waive any claim to severance pay. Furthermore, upon such resignation or termination, Mayne Pharma will have the right to purchase by written notice to O’Donnell or Virca, as the case may be, all Company securities owned by O’Donnell or Virca, including vested options, vested warrants, vested restricted stock units and the like individually held by O’Donnell and/or Virca or otherwise transferred by either of them, as the case may be, at the fair market value (as such term is defined in the Equity Holders Agreement) as of the date of such resignation or termination. The Equity Holders Agreement terminates if (i) the Company receives an adjudication of bankruptcy, the Company executes an assignment for the benefit of creditors, a receiver is appointed for the Company or the Company is voluntarily or involuntarily dissolved or (ii) the Company, HPLLC and Mayne Pharma expressly agree in writing. Additionally, certain limited provisions of the Equity Holders Agreement terminate at such time as the Mayne Pharma Group collectively owns less than ten percent (10%) of the Common Stock on a fully diluted basis. Related Party Debt Forgiveness Agreement Following the Company’s emergence from bankruptcy in August 2013, certain expenses had been incurred for officer salary, travel, legal and patent expenses. These expenses, totaling $639,768, were paid by HPLLC on behalf of the Company. This debt was forgiven pursuant to a Debt Forgiveness Agreement, dated June 24, 2014 (the “Debt Forgiveness Agreement”), which was entered into by the Company and HPLLC as a condition of closing of the Mayne Purchase Agreement and was accounted for as a capital transaction due to the related party nature of the agreement. Pursuant to the Debt Forgiveness Agreement, HPLLC waived, canceled and forgave payment from the Company of the aforementioned $639,768 of indebtedness previously advanced by HPLLC to the Company in exchange for 2,530,227 shares of Common Stock, 71,636 shares of Series A Preferred Stock (the “Debt Forgiveness Series A Shares”) and a warrant (the “Debt Forgiveness Warrant”) to purchase 10,250,569 shares of Common Stock. The Debt Forgiveness Series A Shares together with Series A Preferred Shares previously issued to HPLLC converted into 82,156,842 shares of Common Stock on August 14, 2014 pursuant to the terms of the Equity Holders Agreement and in accordance the with the terms of the Series A Preferred Stock. The Debt Forgiveness Warrant may be exercised by HPLLC at an exercise price of $0.0878 per share at any time, from time to time, prior to the expiration of the Debt Forgiveness Warrant on June 24, 2019.

Liquidity and Management's Plan

Liquidity and Management's Plans	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Text Block [Abstract]
Liquidity and Management's Plans	2. Liquidity and management’s plans: The Company presently has very limited cash resources and requires significant additional financing for its research and development, commercialization and distribution efforts and its working capital and intends to finance these activities primarily through: • public and private financings and, potentially, from strategic transactions; • potential partnerships with other pharmaceutical companies to assist in the supply, manufacturing and distribution of its products for which the Company would expect to receive upfront milestone and royalty payments; • potential licensing and joint venture arrangements with third parties, including other pharmaceutical companies where the Company would receive funding based on out-licensing its product; and • seeking government or private foundation grants which would be awarded to the Company to further develop its current and future anti-cancer therapies. However, there can be no assurance that any of these plans will be implemented or that the Company will be able to obtain additional financing on commercially reasonable terms, if at all. There is substantial doubt about the Company’s ability to continue as a going concern. The Company’s current independent registered public accounting firm has included a paragraph emphasizing “going concern” uncertainty in their audit report on the 2014 financial statements dated February 13, 2015. The financial statements included herein do not include any adjustments relating to the recoverability or classification of asset carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The Company had cash and cash equivalents of approximately $84,000 as of March 31, 2015 and approximately $7,000 as of May 13, 2015. The Company is currently negotiating a common stock and equity financing with a significant stockholder which would bolster our cash balance. No assurances can be given, however, that the Company will be able to close such financing.	2. Liquidity and management’s plans: The Company presently has very limited cash resources and requires significant additional financing for its research and development, commercialization and distribution efforts and its working capital and intends to finance these activities primarily through: • public and private financings and, potentially, from strategic transactions; • potential partnerships with other pharmaceutical companies to assist in the supply, manufacturing and distribution of its products for which the Company would expect to receive upfront milestone and royalty payments; • potential licensing and joint venture arrangements with third parties, including other pharmaceutical companies where the Company would receive funding based on out-licensing its product; and • seeking government or private foundation grants which would be awarded to the Company to further develop its current and future anti-cancer therapies. However, there can be no assurance that any of these plans will be implemented on commercially reasonable terms, if at all. The Company had cash and cash equivalents of $365,161 as of December 31, 2014.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies: Estimates The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income is recognized when earned by the Company. Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts which is $250,000 for substantially all depository accounts. As of March 31, 2015, the Company had did not have any depository accounts containing a cash balance in excess of these insured limits. Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company and purchased in-process research and development. Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of equity securities issued are determined by the Company based predominantly on the trading price of the common stock. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award. Income Taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the condensed financial statements for the three months ended March 31, 2015 or 2014. Recent accounting pronouncements: In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements of Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition” and most industry-specific guidance on revenue recognition throughout the ASC. The new standard is principles-based and provides a five step model to determine when and how revenue is recognized. The core principle of the new standard is that revenue should be recognized when a company transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also requires disclosure of qualitative and quantitative information surrounding the amount, nature, timing and uncertainty of revenues and cash flows arising from contracts with customers. The new standard will be effective for the Company in the first quarter of the year ending December 31, 2017 and can be applied either retrospectively to all periods presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is not permitted. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities.	3. Summary of Significant Accounting Policies: Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements of Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition” and most industry-specific guidance on revenue recognition throughout the ASC. The new standard is principles-based and provides a five step model to determine when and how revenue is recognized. The core principle of the new standard is that revenue should be recognized when a company transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also requires disclosure of qualitative and quantitative information surrounding the amount, nature, timing and uncertainty of revenues and cash flows arising from contracts with customers. The new standard will be effective for the Company for annual reporting periods beginning after December 15, 2016 and can be applied either retrospectively to all periods presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is not permitted. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities. Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income is recognized when earned by the Company. Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts of $250,000 for substantially all accounts. As of December 31, 2014, the Company had approximately $15,000 in excess of the amount covered by Federal Deposit Insurance Corporation with one financial institution. Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company as well as purchased in-process research and development. Accounting for Enterprises in Reorganization Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 852— Reorganizations Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employess using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of equity securities issued are determined by the Company based predominantly on the trading price of the common stock. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award. Income taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. See Note 7 for details. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the consolidated financial statements for the years ended December 31, 2014 or 2013.

Prepaid Expenses

Prepaid Expenses	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Other Income and Expenses [Abstract]
Prepaid Expenses	4. Prepaid Expenses: At March 31, 2015, prepaid expenses of $43,723 consist primarily of premiums related to the Company’s directors and officers insurance. Prepaid expenses of $97,817 at December 31, 2014 consist primarily of $60,000 in professional fees related to a potential registered securities offering that were expensed during the three months ended March 31, 2015 and approximately $40,000 related to directors and officers insurance premiums.	4. Prepaid Expenses: At December 31, 2014, prepaid expenses of $97,817 consisted primarily of $60,000 in expenses relating to the Company’s proposed S-1 Offering and approximately $40,000 relating to the Company’s Directors and Officers insurance premiums. The $10,000 in prepaid expenses at December 31, 2013 related to financing fees that were expensed during 2014.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable On August 1, 2013, the Company formalized amounts due to two former employees and a former director of CBI by issuing three non-interest bearing promissory notes. The two employee notes totaling approximately $62,000 were due on November 1, 2013. Interest began accruing at 18% per annum on the unpaid principal on November 1, 2013, in accordance with the specified terms. On January 31, 2014, the Company extended the two former employee notes to March 31, 2014 while adding accrued interest through January 31, 2014 and an additional $3,000 to the principal balance of each. Additional extensions were entered into in May 2014 to extend the maturity to July 12, 2014, which includes additional principal of approximately $9,000 each along with accrued and unpaid interest through May 13, 2014. On July 10, 2014, a partial payment of $57,000 was made by the Company and the maturity was extended to December 31, 2014, with an interest rate of 9% per annum effective July 10, 2014. The notes balances, including accrued interest, were paid in full in December 2014. The former director non-interest bearing note of approximately $6,000 was due the later of five days following the date on which the Company has raised $1 million, or November 1, 2013. Interest began accruing at a rate of 5% per annum on November 1, 2013 in accordance with the specified terms. The former director note and the related accrued interest were paid in full on July 2, 2014.

Other Liabilities

Other Liabilities	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Other Liabilities Disclosure [Abstract]
Other Liabilities	5. Other liabilities At March 31, 2015 and December 31, 2014 other liabilities include $52,500 payable to a third party service provider for which the Company has agreed to issue a number of restricted shares of its Common Stock to be determined based on the valuation of the shares to be issued to purchasers in connection with the Company’s offering of securities as described in Commonwealth Biotechnology, Inc.’s (“CBI”) Amended Plan of Reorganization filed in 2013. Such shares of Common Stock are to be issued to such service provider within five (5) business days of the final determination of such valuation (as memorialized in the final transaction documentation for such offering).	6. Other liabilities Pursuant to the Contribution Agreement dated August 13, 2013, the Company has agreed to issue to a third party service provider a number of restricted shares of its Common Stock to be determined based on the valuation of the shares to be issued to purchasers in connection with the Company’s planned offering of securities as described in CBI’s Amended Plan of Reorganization in payment of a $52,500 claim. Such shares of Common Stock are to be issued to such service provider within five (5) business days of the final determination of such valuation (as memorialized in the final transaction documentation for such offering). The $52,500 is included in the balance of other liabilities in the Balance Sheets for December 31, 2014 and 2013. Additional accrued amounts for unbilled legal expenses and research and development are included in the December 31, 2014 total of $73,178.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes: The difference between expected income tax benefits and income tax benefit recorded in the financial statements is explained below: December 31, 2014 2013 Income taxes (benefit) computed at statutory rate $ (1,351,601 ) $ (627,319 ) State income tax benefit, net (137,219 ) (63,688 ) Other 80,899 — Change in valuation allowance 1,407,921 691,007 $ — $ — The significant components of deferred income tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2014 2013 In-process research and development $ 996,154 $ 346,801 Net operating loss carry forward 878,706 407,398 R&D credit 15,779 2,584 Share-based compensation 256,219 — Accrued expenses 17,850 — 2,164,708 756,783 Less: valuation allowance (2,164,708 ) (756,783 ) $ — $ — In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation allowance should be sufficient to reduce the deferred tax asset to the amount which is more likely than not to be realized. As a result, the Company recorded a valuation allowance with respect to all of the Company’s deferred tax assets. The Company has a federal net operating loss (“NOLs”) of approximately $2.4 million as of December 31, 2014. Under Section 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a “loss corporation”, as defined, there are annual limitations on the amount of the NOLs and other deductions which are available to the Company. The portion of the NOLs incurred prior to August 12, 2013 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $35,000 per year and the Company has written off the deferred tax assets associated with the NOLs limited due to the ownership change that occurred on August 12, 2013. The Company’s State NOLS are approximately $2.2 million as of December 31, 2013. The loss carryforwards begin to expire in 2018.

Chapter 11 Information

Chapter 11 Information	12 Months Ended
	Dec. 31, 2014
Reorganizations [Abstract]
Chapter 11 Information	8. Chapter 11 Information: During the year ended December 31, 2013, the Company settled all pre-petition claims associated with the bankruptcy in cash and Common Stock. The Company paid $357,265 in cash and $152,000 in Common Stock to settle the claims. The Common Stock was valued using the 30 day average of the Company’s stock price. The $166,676 difference between pre-petition liabilities and the settled amount was recognized as gain on reorganization in the accompanying statement of operations for the year ended December 31, 2013. There was no such gain for the year ended December 31, 2014.

Stockholders' Equity

Stockholders' Equity	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	6. Stockholders’ Equity: Employee Stock Plans On July 18, 2014, a 2014 Equity Incentive Plan (“EIP”) was adopted by the Company’s Board of Directors. On September 30, 2014, the EIP was approved by the majority of stockholders. The 2014 EIP authorizes the issuance of up to 32,583,475 shares of the Company’s common stock. In July 2014, 15,041,738 Restricted Stock Units (“RSUs”) were granted to the Company’s Chief Executive Officer, Nicholas J. Virca, and shall vest upon the earlier to occur of (i) September 3, 2016 or (ii) the acceptance by the FDA of a New Drug Application (“NDA”) by the Company for any Company product candidate with a cancer indication utilizing the Company’s licensed SUBA-itraconazole technology, provided that Mr. Virca is actively employed by the Company on the earlier of such date. An additional 1.5 million RSUs were issued to various Board members and officers with the same vesting schedule. In August 2014, 7,000,000 RSUs were issued to the Company’s Chief Financial Officer, Garrison J. Hasara. Of those RSUs, 50% shall vest upon the earlier to occur of (i) September 3, 2016 or (ii) the acceptance by the FDA of a NDA by the Company for any Company product candidate with a cancer indication utilizing the Company’s licensed SUBA-itraconazole technology, provided that Mr. Hasara is actively employed by the Company on the earlier of such date. The balance of the RSUs will vest September 3, 2017. Going forward, incentive awards may be in the form of stock options, restricted stock, restricted stock units and performance and other awards. In the case of incentive stock options, the exercise price will not be less than 100% of the fair market value of shares covered at the time of the grant, or 110% for incentive stock options granted to persons who own more than 10% of the Company’s voting stock. Options granted will generally vest over a three-year period from the date of grant and will be exercisable for ten years, except that the term may not exceed five years for incentive stock options granted to persons who own more than 10% of the Company’s outstanding common stock. Total stock-based compensation for the three months ended March 31, 2015 was $419,703, is related to certain RSUs issued in 2014 and is classified as research and development expense and general and administrative expense in the accompanying condensed 2015 statement of operations. There was approximately $2.6 million in unamortized stock-based compensation relating the RSUs at March 31, 2015, which is expected to be recognized over the next 30 months. The fair value of RSUs was determined using the quoted market price of the Company’s common stock on the date of issuance and the number of shares expected to vest.	9. Stockholders’ Equity: Employee Stock Plans A 2002 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. However, all options were canceled on July 16, 2013, which was 90 days subsequent to the effective date of the emergence from bankruptcy. A 2007 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. However, all options were canceled on July 16, 2013, which was 90 days subsequent to the effective date of the emergence from bankruptcy. A 2009 Stock Incentive Plan was adopted by the Board of Directors and approved by the shareholders of CBI. There are no options outstanding under this plan. On July 18, 2014, a 2014 Equity Incentive Plan (“EIP”) was adopted by the Company’s Board of Directors. On September 30, 2014, the EIP was approved by the majority of stockholders. The 2014 EIP authorizes the issuance of up to 32,583,475 shares of the Company’s common stock. In July 2014, 15,041,738 restricted stock units (“RSUs”) were granted to the Company’s Chief Executive Officer, Nicholas J. Virca, and shall vest upon the earlier to occur of (i) September 3, 2016 or (ii) the acceptance by the FDA of a New Drug Application (“NDA”) by the Company for any Company product candidate with a cancer indication utilizing the Company’s licensed SUBA-itraconazole technology, provided that Mr. Virca is actively employed by the Company on the earlier of such date. An additional 1.5 million RSUs were issued to various Board members and officers with the same vesting schedule. In August 2014, 7,000,000 RSUs were issued to the Company’s Chief Financial Officer, Garrison J. Hasara. Of those RSUs, 50% shall vest upon the earlier to occur of (i) September 3, 2016 or (ii) the acceptance by the FDA of a NDA by the Company for any Company product candidate with a cancer indication utilizing the Company’s licensed SUBA-itraconazole technology, provided that Mr. Hasara is actively employed by the Company on the earlier of such date. The balance of the RSUs will vest September 3, 2017. Going forward, incentive awards may be in the form of stock options, restricted stock, restricted stock units and performance and other awards. In the case of incentive stock options, the exercise price will not be less than 100% of the fair market value of shares covered at the time of the grant, or 110% for incentive stock options granted to persons who own more than 10% of the Company’s voting stock. Options granted will generally vest over a three-year period from the date of grant and will be exercisable for ten years, except that the term may not exceed five years for incentive stock options granted to persons who own more than 10% of the Company’s outstanding common stock. Stock-based compensation expense is determined based on the fair value of the stock-based awards and recognized over the vesting period. The Company recognized $753,585 in stock-based compensation expense related to Restricted Stock Units for the year ended December 31, 2014. There was no comparable expense for the year ended December 31, 2013. As of December 31, 2014 there was approximately $3.0 million in unamortized stock-based compensation cost related to non-vested stock awards. Stock option activity for the years ended December 31, 2014 and 2013 is as follows: Number of Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding at December 31, 2012 245,443 $ 3.02 $ — Granted in 2013 — — — Exercised — — — Canceled (245,443 ) 3.02 — Outstanding at December 31, 2013 — — — Granted in 2014 — — — Exercised — — — Outstanding at December 31, 2014 — $ — $ — Issuance of Restricted Stock In April 2013, restricted shares were issued to CBI’s CEO, one CBI board member and one former CBI officer for a portion of their approved claims. The number of shares issued, which totaled 3,328,467, was determined by using a per share price equal to the average of the 30 day closing price of Common Stock and was valued at $152,000. Issuance of Preferred and Common Stock Upon entering into the Amended and Restated Supply and License Agreement with Mayne Pharma, the Company issued 258,363 shares of Series A Preferred Stock to Mayne Pharma. The fair value of such issued shares of Series A Preferred Stock has been accounted for as in-process research and development totaling approximately $1.3 million and is included in research and development expense for the year ended December 31, 2014. See Note 1 for discussion of Series A Preferred Stock issued for related party debt forgiveness. See Note 1 for discussion of Common Stock issued. Warrants Pursuant to the Mayne Purchase Agreement (Note 1), a warrant to purchase 10,250,569 shares of the Company’s common stock at $0.0878 were granted to Mayne Pharma. The warrant will expire on June 24, 2019. The fair value of warrants has been accounted for as in-process research and development totaling approximately $0.6 million and is included in research and development expense for the year ended December 31, 2014. Pursuant to the Debt Forgiveness Agreement (Note 1) with HPLLC, a warrant to purchase 10,250,569 shares of the Company’s common stock at $0.0878 was granted to HPLLC. The warrant will expire on June 24, 2019. The amount of debt forgiven of $450,000 was recorded as additional paid-in capital for the year ended December 31, 2014.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	10. Related party transactions: As part of the short-form reincorporation merger with HPPI, certain expenses had been incurred for officer salary, travel, legal and patent expense. These expenses, totaling $366,130, were paid by Hedgepath, LLC on behalf of the newly formed HPPI and are included in due to related party in the accompanying balance sheet as of December 31, 2013. An additional $273,638 was advanced during 2014. The balance of $639,768 was exchange for preferred stock, common stock and common stock warrants as discussed further in note 1 ( Related Party Debt Forgiveness Agreement).

Legal Proceedings

Legal Proceedings	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	7. Legal Proceedings: Chien Connecticut Case In October 2012, Andrew Chien (“Chien”), an alleged shareholder of our predecessor, CBI, filed suit in Connecticut state court (later removed to the United States District Court for the District of Connecticut (the “CT District Court”)) against CBI, Dr. Richard J. Freer (a director and officer of CBI) (“Freer”), and the law firm LeClairRyan (the “Chien Connecticut Case”). In October 2012, the CT District Court in the Chien Connecticut Case entered an Order dismissing Chien’s claims without prejudice on account of CBI’s pending Chapter 11 bankruptcy. Chien filed various motions in response to the CT District Court’s decision dismissing the claims asserted against Freer and LeClairRyan, including a motion for reconsideration. On Thursday, May 29, 2014, the presiding judge issued several orders. The CT District Court granted Chien’s request that he be allowed to proceed with the fifth and six claims he asserted against CBI in his Complaint, namely (i) a claim for relief entitled “Securities Fraud and Fiduciary Duty Violation against CBI” and (ii) a claim for relief entitled “Fiduciary Duty violation against CBI” (collectively, the “Chien Claims”). A related scheduling order provided that CBI had until June 20, 2014 to answer or otherwise respond to the Complaint. We have retained LeClairRyan to serve as CBI’s counsel in the Chien Connecticut Case. On June 20, 2014, LeClairRyan filed on CBI’s behalf a motion to dismiss seeking a dismissal with prejudice of the Chien Claims. LeClairRyan also filed on CBI’s behalf a motion to stay discovery. On August 5, 2014, the CT District Court granted CBI’s motion to stay discovery. On November 4, 2014, the CT District Court dismissed the case and the matter was closed by the CT District Court. On December 1, 2014, Chien filed various motions including a Motion to Reargue. In response, the Company filed a consolidated opposition to Chien’s various pleadings, including to the Motion to Reargue. The Company is now awaiting a decision from the CT District Court. The Company strongly refutes as without merit Chien’s claims and will continue to vigorously defend the lawsuit. You should rely only on the information contained in this document. We have not authorized anyone to provide you with information that is different. This document may only be used where it is legal to sell these securities. The information in this document may only be accurate on the date of this document. Additional risks and uncertainties not presently known or that are currently deemed immaterial may also impair our business operations. The risks and uncertainties described in this document and other risks and uncertainties which we may face in the future will have a greater impact on those who purchase our common stock. These purchasers will purchase our common stock at the market price or at a privately negotiated price and will run the risk of losing their entire investment.	11. Legal Proceedings: Chien Connecticut Case In October 2012, Andrew Chien (“Chien”), an alleged shareholder of the Company’s predecessor, CBI, filed suit in Connecticut state court (later removed to the United States District Court for the District of Connecticut (the “CT District Court”)) against CBI, Dr. Richard J. Freer (a director and officer of CBI) (“Freer”), and the law firm LeClairRyan (the “Chien Connecticut Case”). In October 2012, the CT District Court in the Chien Connecticut Case entered an Order dismissing Chien’s claims without prejudice on account of CBI’s pending Chapter 11 bankruptcy. Chien filed various motions in response to the CT District Court’s decision dismissing the claims asserted against Freer and LeClairRyan, including a motion for reconsideration. On Thursday, May 29, 2014, the presiding judge issued several orders. The CT District Court granted Chien’s request that he be allowed to proceed with the fifth and six claims he asserted against CBI in his Complaint, namely (i) a claim for relief entitled “Securities Fraud and Fiduciary Duty Violation against CBI” and (ii) a claim for relief entitled “Fiduciary Duty violation against CBI” (collectively, the “Chien Claims”). A related scheduling order provided that CBI had until June 20, 2014 to answer or otherwise respond to the Complaint. The Company retained LeClairRyan to serve as CBI’s counsel in the Chien Connecticut Case. On June 20, 2014, LeClairRyan filed on CBI’s behalf a motion to dismiss seeking a dismissal with prejudice of the Chien Claims. LeClairRyan also filed on CBI’s behalf a motion to stay discovery. On August 5, 2014, the CT District Court granted CBI’s motion to stay discovery. On November 4, 2014, the CT District Court dismissed the case and the matter was closed by the court. On December 1, 2014, Chien filed various motions including a Motion to Reargue. In response, the Company filed a consolidated opposition to Chien’s various pleadings, including to the Motion to Reargue. The Company is now awaiting a decision from the Court. The Company strongly refutes as without merit Chien’s claims and will continue to vigorously defend the lawsuit. Chien Virginia Case In April 2013, Chien filed an adversary proceeding to recover monetary and injunctive relief against CBI and Freer in the United States Bankruptcy Court for the Eastern District of Virginia (the “EDVA Bankruptcy Court”). On June 19, 2013, the EDVA Bankruptcy Court held a hearing on CBI’s and Freer’s motions to strike and / or dismiss Chien’s adversary proceeding Complaint. At the conclusion of the June 19, 2013 hearing the EDVA Bankruptcy Court granted CBI’s and Freer’s motions to strike and / or dismiss and ordered that Chien’s adversary proceeding be dismissed. On July 1, 2013, the EDVA Bankruptcy Court entered a Memorandum Opinion memorializing its decision. Chien perfected an appeal of the EDVA Bankruptcy Court’s decision (the “Bankruptcy Appeal”) to the United States District Court for the Eastern District of Virginia (the “EDVA District Court”). On August 14, 2014, the EDVA District Court dismissed the case and the matter was closed by the court on September 16, 2014. Other On July 24, 2013 and August 5, 2013, purported class actions were filed in the United States District Court for the Middle District of Florida (Tampa Division) against Accentia Biopharmaceuticals, Inc., and several current and former directors and officers of Accentia and its former subsidiary, Biovest International, Inc. (collectively the “Class Action”), including Frank E. O’Donnell, Jr. M.D., the Company’s Executive Chairman. The complaints allege that the defendants violated federal securities laws by making or causing Accentia and/or Biovest to make false statements, and by failing to disclose or causing Accentia and/or Biovest to fail to disclose material information, concerning the results of the clinical trial of Biovest’s cancer vaccine, BiovaxID, and status of its approval by the FDA. Plaintiffs seek damages in an unspecified amount on behalf of shareholders who purchased common stock of Accentia or Biovest during a defined time period. All defendants, including Dr. O’Donnell, believe this litigation to be without merit, deny any wrongdoing or liability and have vigorously defended the alleged claims. A settlement of this matter, in which defendants make no admissions of wrongdoing or liability, has been agreed upon by all parties and approved by the Court.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Recent accounting pronouncements: In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements of Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition” and most industry-specific guidance on revenue recognition throughout the ASC. The new standard is principles-based and provides a five step model to determine when and how revenue is recognized. The core principle of the new standard is that revenue should be recognized when a company transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also requires disclosure of qualitative and quantitative information surrounding the amount, nature, timing and uncertainty of revenues and cash flows arising from contracts with customers. The new standard will be effective for the Company in the first quarter of the year ending December 31, 2017 and can be applied either retrospectively to all periods presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is not permitted. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities.	Recent accounting pronouncements In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers,” which supersedes the revenue recognition requirements of Accounting Standards Codification (“ASC”) Topic 605, “Revenue Recognition” and most industry-specific guidance on revenue recognition throughout the ASC. The new standard is principles-based and provides a five step model to determine when and how revenue is recognized. The core principle of the new standard is that revenue should be recognized when a company transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The new standard also requires disclosure of qualitative and quantitative information surrounding the amount, nature, timing and uncertainty of revenues and cash flows arising from contracts with customers. The new standard will be effective for the Company for annual reporting periods beginning after December 15, 2016 and can be applied either retrospectively to all periods presented or as a cumulative-effect adjustment as of the date of adoption. Early adoption is not permitted. The Company will evaluate the impact of adoption of the new standard on its financial statements upon commencement of revenue generating activities.
Estimates	Estimates The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.	Estimates The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income is recognized when earned by the Company.	Revenue Recognition The Company currently has no ongoing source of revenues. Miscellaneous income is recognized when earned by the Company.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts which is $250,000 for substantially all depository accounts. As of March 31, 2015, the Company had did not have any depository accounts containing a cash balance in excess of these insured limits.	Cash and Cash Equivalents The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. At times, the Company may maintain cash balances in excess of Federal Deposit Insurance Corporation insured amounts of $250,000 for substantially all accounts. As of December 31, 2014, the Company had approximately $15,000 in excess of the amount covered by Federal Deposit Insurance Corporation with one financial institution.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company and purchased in-process research and development.	Research and Development Expenses Research and development costs are expensed in the period in which they are incurred and include the expenses paid to third parties who conduct research and development activities on behalf of the Company as well as purchased in-process research and development.
Accounting for Enterprises in Reorganization		Accounting for Enterprises in Reorganization Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 852— Reorganizations
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employees using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of equity securities issued are determined by the Company based predominantly on the trading price of the common stock. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award.	Stock-Based Compensation The Company accounts for stock-based awards to employees and non-employess using Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718 – Accounting for Share-Based Payments, which provides for the use of the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of equity securities issued are determined by the Company based predominantly on the trading price of the common stock. The value of these awards is based upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award.
Income taxes	Income Taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the condensed financial statements for the three months ended March 31, 2015 or 2014.	Income taxes Deferred tax assets and liabilities are recognized for future tax consequences attributed to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases and are measured using enacted tax rates that are expected to apply to the differences in the periods that they are expected to reverse. See Note 7 for details. Management has evaluated the guidance relating to accounting for uncertainty in income taxes and has determined that the Company had no uncertain income tax positions that could have a significant effect on the consolidated financial statements for the years ended December 31, 2014 or 2013.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Difference Between Expected Income Tax Benefits and Income Tax Benefit Recorded in the Financial Statements	The difference between expected income tax benefits and income tax benefit recorded in the financial statements is explained below: December 31, 2014 2013 Income taxes (benefit) computed at statutory rate $ (1,351,601 ) $ (627,319 ) State income tax benefit, net (137,219 ) (63,688 ) Other 80,899 — Change in valuation allowance 1,407,921 691,007 $ — $ —
Components of Deferred Income Tax Assets and Liabilities	The significant components of deferred income tax assets and liabilities consist of the following: December 31, Deferred tax assets (liabilities) 2014 2013 In-process research and development $ 996,154 $ 346,801 Net operating loss carry forward 878,706 407,398 R&D credit 15,779 2,584 Share-based compensation 256,219 — Accrued expenses 17,850 — 2,164,708 756,783 Less: valuation allowance (2,164,708 ) (756,783 ) $ — $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Summary of Stock Option Activity	Stock option activity for the years ended December 31, 2014 and 2013 is as follows: Number of Shares Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding at December 31, 2012 245,443 $ 3.02 $ — Granted in 2013 — — — Exercised — — — Canceled (245,443 ) 3.02 — Outstanding at December 31, 2013 — — — Granted in 2014 — — — Exercised — — — Outstanding at December 31, 2014 — $ — $ —

Corporate Overview - Additional

Corporate Overview - Additional Information (Detail)	Aug. 14, 2014USD ($)shares	Jun. 24, 2014USD ($)$ / sharesshares	Aug. 13, 2013USD ($)shares	Aug. 12, 2013$ / sharesshares	Mar. 29, 2013	Jan. 04, 2013USD ($)	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)Director$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, par value | $ / shares							$ 0.0001		$ 0.0001	$ 0.0001
Total percentage of issued and outstanding shares of HPPI common stock					100.00%
Ownership interest exchanged for the assets contributed					90.00%
Common stock, shares issued							211,419,937		211,419,937	18,888,971
Value of securities planned to offer as a part of contribution agreement | $										$ 5,000,000
Maximum number of days after determination of valuation within which the securities should be offered							5 days		5 days	5 days
Research and development expense | $							$ 313,017	$ 25,325	$ 2,430,735	$ 1,065,169
Supply and License Agreement from the date of the first commercial sale of the product							10 years		10 years
Preferred stock , shares Issued									0	0
Mayne Pharma Securities Purchase Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock , shares Issued		258,363
Warrant share, issued		10,250,569
Converted common stock | $	$ 87,843,897
Warrant exercise price | $ / shares		$ 0.0878
Market capitalization agreement rate		42.00%
Ownership exchanged agreement rate		42.00%
Debt Forgiveness Warrant expiration period		Jun. 24, 2019
Contribution Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of voting rights retained by the prior stockholders of CBI in HPPI					10.00%
Common stock, shares issued			170,000,739
Mayne Pharma, HPLLC, Virca and O'Donnell [Member] | Maximum [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Ownership exchanged agreement rate									49.50%
Mayne Pharma [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Number of directors for immediate placement | Director									1
Number of total directors for the addition of a Mayne Pharma placed director | Director									7
Mayne Pharma [Member] | Maximum [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Right to participate in private offerings									50.00%
Mayne Pharma [Member] | Minimum [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of voting right									10.00%
Commonwealth Biotechnologies, Inc. [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Conversion ratio				1
Hedgepath, LLC's claim against CBI | $										$ 52,500
Hedgepath LLC [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Auction fees paid by Hedgepath, LLC to CBI | $						$ 30,000
Percentage of market capitalization of assets			90.00%
Percentage of ownership exchanged for the assets			90.00%
Warrant share, issued									10,250,569
Warrant exercise price | $ / shares									$ 0.0878
Debt Forgiveness Warrant expiration period									Jun. 24, 2019
Common stock issued under stock purchase agreement, shares		20,000,000
Common stock issued under stock purchase agreement, price per share | $ / shares		$ 0.075
Aggregate purchase price for common stock issued under stock purchase agreement | $		$ 1,500,000
Hedgepath LLC [Member] | Contribution Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Expenses incurred for acquiring assets and developing ITRA business opportunity | $									$ 100,000
Expenses incurred on technical and medical consulting | $									82,500
Expenses incurred on option fees | $									$ 15,000
Hedgepath LLC [Member] | Related Party Debt Forgiveness Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, shares issued		2,530,227
Warrant share, issued		10,250,569
Warrant exercise price | $ / shares									$ 0.0878
Debt Forgiveness Warrant expiration period									Jun. 24, 2019
Issuance of stock and warrants in debt forgiveness transaction | $									$ 639,768
Converted common stock pursuant to the terms of the equity holders agreement	82,156,842
Series A Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock , shares Issued									0	170,001
Common stock issued under stock purchase agreement, shares										170,001
Series A Preferred Stock [Member] | Contribution Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Percentage of convertible preferred stock representing diluted voting securities			90.00%
Number of shares in exchange for right to receive			170,001
Series A Preferred Stock [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock shares to be forfeited									17,647
Series A Preferred Stock [Member] | Mayne Pharma and HPLLC [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Common stock, conversion basis									At a rate of 1 for 340 shares of Common Stock
Preferred stock converted to common stock	500,000
Series A Preferred Stock [Member] | Hedgepath LLC [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock shares to be forfeited									17,647
Common Stock following conversion of preferred stock									6,000,000
Series A Preferred Stock [Member] | Hedgepath LLC [Member] | Related Party Debt Forgiveness Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Preferred stock , shares Issued		71,636
Preferred Stock and Warrant [Member] | Mayne Pharma Securities Purchase Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Research and development expense | $		$ 1,900,000
Warrants [Member] | Mayne Pharma Securities Purchase Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Expected volatility rate used for calculation of value of warrant		104.90%
Expected term used for calculation of value of warrant		5 years
Risk free interest rate used in calculation of value of warrant		1.70%
Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Par value assigned stock after merger | $ / shares				$ 0.0001
Common stock issued under stock purchase agreement, shares									20,000,000
Common Stock [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of HPPI's shares to CBI's shareholders, stock				340,000,000
Common Stock [Member] | Series A Preferred Stock [Member] | Mayne Pharma and HPLLC [Member] | Equity Holders Agreement [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Converted common stock	170,000,739
Preferred Stock [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Par value assigned stock after merger | $ / shares				$ 0.0001
Preferred Stock [Member] | Maximum [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Issuance of HPPI's shares to CBI's shareholders, stock				10,000,000
Preferred Stock [Member] | Hedgepath LLC [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Research and development expense | $			$ 1,000,000

Liquidity and Management's Pl22

Liquidity and Management's Plans - Additional Information (Detail) - USD ($)	May. 13, 2015	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Bankruptcy [Line Items]
Cash and cash equivalents		$ 83,951	$ 365,161	$ 456	$ 217	$ 857,702
Subsequent Event [Member]
Bankruptcy [Line Items]
Cash and cash equivalents	$ 7,000

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Cash, FDIC Insured Amount	$ 250,000	$ 250,000
Cash balance in excess of amount covered by Federal Deposit Insurance Corporation	$ 0	$ 15,000

Prepaid Expenses - Additional I

Prepaid Expenses - Additional Information (Detail) - USD ($)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses		$ 97,817	$ 10,000
Board Members and Officers [Member]
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses	$ 43,723
Board Members and Officers [Member] | Insurance Premiums [Member]
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses	40,000	40,000
Proposed S-1 Offering [Member] | Professional Fees [Member]
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses		$ 60,000
Potential S-1 Offering [Member] | Professional Fees [Member]
Disclosure Prepaid Expenses And Other Assets Details [Line Items]
Prepaid expenses	$ 60,000

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - Promissory Notes [Member]	Jul. 10, 2014USD ($)	Aug. 01, 2013USD ($)EmployeesPromissory_Notes	May. 31, 2014USD ($)	Jan. 31, 2014USD ($)
Debt Instrument [Line Items]
Number of non-interest promissory notes | Promissory_Notes		3
Number of employees for notes | Employees		2
Promissory note due period		5 days
Fund amount to be raise under condition one		$ 1,000,000
Expected maturity date under condition two		Nov. 1, 2013
Employees [Member]
Debt Instrument [Line Items]
Notes due		$ 62,000	$ 9,000	$ 3,000
Interest to be paid on default of promissory note		18.00%
Debt interest rate	9.00%
Debt Instrument, Periodic Payment, Principal	$ 57,000
Board Member [Member]
Debt Instrument [Line Items]
Notes due		$ 6,000
Interest to be paid on default of promissory note		5.00%

Other Liabilities - Additional

Other Liabilities - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 13, 2013
Other Liabilities [Line Items]
Maximum number of days after determination of valuation within which the securities should be offered	5 days	5 days	5 days
Accrued unbilled legal , research and development expenses		$ 73,178
Commonwealth Biotechnology, Inc. [Member]
Other Liabilities [Line Items]
Payment of claim against CBI's Amended Plan	$ 52,500	$ 52,500	$ 52,500	$ 52,500

Income Taxes - Difference betwe

Income Taxes - Difference between expected income tax benefits and income tax benefit recorded in the financial statements (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income taxes (benefit) computed at statutory rate	$ (1,351,601)	$ (627,319)
State income tax benefit, net	(137,219)	(63,688)
Other	80,899
Change in valuation allowance	1,407,921	691,007
Expected income tax benefits and income tax benefits recorded	$ 0	$ 0

Income Taxes - Components of de

Income Taxes - Components of deferred income tax assets and liabilities (Detail) - USD ($)	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
In-process research and development	$ 996,154	$ 346,801
Net operating loss carry forward	878,706	407,398
R&D credit	15,779	2,584
Share-based compensation	256,219
Accrued expenses	17,850
Deferred tax assets gross	2,164,708	756,783
Less: valuation allowance	(2,164,708)	(756,783)
Deferred tax assets, net	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - Dec. 31, 2014 - USD ($)	Total
Income Taxes [Line Items]
NOLs used to offset taxable income	$ 35,000
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Net operating loss carryforward	2,400,000
State and Local Jurisdiction [Member]
Income Taxes [Line Items]
Net operating loss carryforward	$ 2,200,000
Operating loss carryforward expiration period	Dec. 31, 2018

Chapter 11 Information - Additi

Chapter 11 Information - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Reorganizations [Abstract]
Pre-petition claims associated with the bankruptcy in cash		$ 357,265
Pre-petition claims associated with the bankruptcy in common Stock		$ 152,000
Common stock value in average of the company's stock price		30 days
Gain on reorganization	$ 0	$ 166,676

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Jul. 16, 2013	Aug. 31, 2014shares	Jul. 31, 2014shares	Apr. 30, 2013USD ($)EmployeeOfficeshares	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)shares	Dec. 31, 2012shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option outstanding under 2009 stock incentive plan							0	0	245,443
Unamortized stock-based compensation cost related to RSU recognition period					30 months		3 years
Period considered to compute average closing price of common stock								30 days
Preferred stock, shares issued							0	0
Research and development expenses | $					$ 313,017	$ 25,325	$ 2,430,735	$ 1,065,169
Additional paid-in capital | $							450,000
Total Stock based compensation expense | $					419,703		$ 753,585
Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares issued							0	170,001
Mayne [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued during the period							10,250,569
Warrant exercise price | $ / shares							$ 0.0878
Warrant expiration date							Jun. 24, 2019
Mayne [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value adjustment of warrants | $							$ 600,000
Mayne [Member] | Series A Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares issued							258,363
Research and development expenses | $							$ 1,300,000
Hedgepath LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants issued during the period							10,250,569
Warrant exercise price | $ / shares							$ 0.0878
Warrant expiration date							Jun. 24, 2019
Hedgepath LLC [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional paid-in capital | $							$ 450,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Stock based compensation expense related to RSU | $							$ 753,585	$ 0
Unamortized stock-based compensation cost related to non-vested stock awards | $					2,600,000
Total Stock based compensation expense | $					$ 419,703
Restricted Stock Units (RSUs) [Member] | CEO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs issued to Chief Financial Officer		7,000,000
RSUs vesting percentage		50.00%
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted vesting period					3 years		3 years
Period during which options are exercisable					10 years		10 years
Employee Stock Option [Member] | More Than 10% Common Stock Owners [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price as percentage of fair market value of shares					110.00%		110.00%
Minimum percentage of the company's voting stock ownership for 110% exercise price of stock options					10.00%		10.00%
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price as percentage of fair market value of shares					100.00%		100.00%
Employee Stock Option [Member] | Maximum [Member] | More Than 10% Common Stock Owners [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period during which options are exercisable					5 years		5 years
Nonvested Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unamortized stock-based compensation cost related to non-vested stock awards | $							$ 3,000,000
Commonwealth Biotechnologies, Inc. [Member] | Ceo Board Member And Former Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period considered to compute average closing price of common stock				30 days
Number of board member to whom restricted shares were issued | Employee				1
Number of former officer to whom restricted shares were issued | Office				1
Commonwealth Biotechnologies, Inc. [Member] | Restricted Stock [Member] | Ceo Board Member And Former Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock issued during the period				3,328,467
Market value of restricted stock issued during the period | $				$ 152,000
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option outstanding under 2009 stock incentive plan							0
Equity Incentive Plan [Member] | 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized to be issued under Equity Incentive Plan					32,583,475		32,583,475
Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | 2014 [Member] | CEO [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock issued during the period			15,041,738				15,041,738
Equity Incentive Plan [Member] | Restricted Stock Units (RSUs) [Member] | 2014 [Member] | Board Members and Officers [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock issued during the period					1,500,000		1,500,000
2002 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of cancellation of options	90 days
Options cancellation date	Jul. 16, 2013
2007 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period of cancellation of options	90 days
Options cancellation date	Jul. 16, 2013

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Outstanding Shares, Beginning Balance	0	245,443
Outstanding Shares, Granted	0	0
Outstanding Shares, Exercised	0	0
Outstanding Shares, Canceled		(245,443)
Outstanding Shares, Ending Balance	0	0
Weighted Average Exercise Price, Beginning balance	$ 0	$ 3.02
Weighted Average Exercise Price, Granted	0	0
Weighted Average Exercise Price, Exercisable	0	0
Weighted Average Exercise Price, Cancelled		3.02
Weighted Average Exercise Price, Ending balance	$ 0	$ 0
Aggregate Intrinsic Value, Beginning balance	$ 0	$ 0
Aggregate Intrinsic Value, Ending balance	$ 0	$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Due to Hedgepath LLC		$ 366,130
Hedgepath LLC [Member]
Related Party Transaction [Line Items]
Due to Hedgepath LLC	$ 273,638	$ 366,130
Amount exchanged for preferred stock, common stock and common stock warrants	$ 639,768